DNA gag/Adenovirus Type 5 (Ad5) gag and Ad5 gag/Ad5 gag Vaccines Induce Distinct T-Cell Response Profiles

Results from Merck's phase II adenovirus type 5 (Ad5) gag/pol/nef test-of-concept trial showed that the vaccine lacked efficacy against human immunodeficiency virus (HIV) infection in a high-risk population. Among the many questions to be explored following this outcome are whether (i) the Ad5...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Cox, Kara S., Clair, James H., Prokop, Michael T., Sykes, Kara J., Dubey, Sheri A., Shiver, John W., Robertson, Michael N., Casimiro, Danilo R.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society for Microbiology (ASM) 2008
Materias:
Vaccines and Antiviral Agents
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2519591/
https://ncbi.nlm.nih.gov/pubmed/18524823
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.00620-08
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares